Paroxysmal nocturnal hemoglobinuria following alemtuzumab immunosuppressive therapy for myelodysplastic syndrome and complicated by recurrent life-threatening thrombosis despite anticoagulation: Successful intervention with eculizumab and fondaparinux
- 30 April 2010
- journal article
- other
- Published by Elsevier BV in Leukemia Research
- Vol. 34 (4), e85-e87
- https://doi.org/10.1016/j.leukres.2009.09.024
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaBlood, 2007
- Heparin-Induced Thrombocytopenia Associated with FondaparinuxNew England Journal of Medicine, 2007
- Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2007
- CD55 and CD59 Deficiency in Transplant Patient Populations: Possible Association With Paroxysmal Nocturnal Hemoglobinuria–Like Symptoms in Campath-Treated PatientsTransplantation Proceedings, 2006
- Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletionBone Marrow Transplantation, 2005
- The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma HemoglobinJAMA, 2005
- Primary prophylaxis with warfarin prevents thrombosis in paroxysmal nocturnal hemoglobinuria (PNH)Blood, 2003
- Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromesThe Hematology Journal, 2001